ATOXYTOR 20mg price in UAE

Overview

Welcome to Dwaey, specifically on ATOXYTOR 20mg Tablet/ Film coated page.
This medicine contains an important and useful components, as it consists of Atorvastatin .
ATOXYTOR 20mg is available in the market in concentration 20 mg/tablet and in the form of Tablet/ Film coated.

PHARMAX PHARMACEUTICALS FZ LLC is the producer of ATOXYTOR 20mg and it is imported from UAE, The most popular alternatives of ATOXYTOR 20mg are listed downward .

Mode Of Action

Atorvastatin competitively inhibits HMG-CoA reductase, the enzyme that catalyses the conversion of HMG-CoA to mevalonate. This results in the induction of the LDL receptors and stimulation of LDL catabolism, leading to lowered LDL-cholesterol levels.

Indication

Primary hypercholesterolemia (heterozygous familial and nonfamilial)
Mixed Dyslipidemia
Homozygous familial hypercholesterolemia
Hypertriglyceridemia
Familial hypercholesterolemia
Cardiovascular event prevention
Primary dysbetalipoproteinemia

Precaution

Patients who consume substantial quantities of alcohol. History of liver disease. Patients with risk factors for myopathy or rhabdomyolysis. Hypothyroidism should be properly managed prior to starting statin therapy. Children <10 yr. Premenarcheal females. Lactation: Because of the potential for adverse reactions in nursing infants, women taking this drug should not breastfeed; contraindicated in nursing mothers.

Side Effects

>10% Diarrhea (5-14%)
Nasopharyngitis (4-13%)
Arthralgia (4-12%) 1-10% Insomnia (1-5%)
Urinary tract infection (4-8%)
Nausea (4-7%)
Dyspepsia (3-6%)
Increased transaminases (2-3%)
Muscle spasms (2-5%)
Musculoskeletal pain (2-5%)
Myalgia (3-8%)
Limb pain (3-8%)
Pharyngolaryngeal pain (1-4%) Frequency Not Defined Angina
Syncope
Dyspnea
Myopathy
Anaphylaxis
Stevens-Johnson syndrome
Myositis Potentially Fatal: Thrombocytopenia. Rhabdomyolysis with acute renal failure.

Contra indication

Hypersensitivity, active liver disease or unexplained persistent elevations of serum transaminase, porphyria, pregnancy, lactation.

Pregnancy and lactation

Pregnancy category: X

Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

Interaction

May increase risk of myopathy and rhabdomyolysis w/ CYP3A4 potent inhibitor (e.g. HIV or HCV protease inhibitors, itraconazole, clarithromycin), fenofibrate, colchicines, fixed combination of lopinavir/ritonavir. May decrease plasma concentration w/ CYP3A4 inducer (e.g. rifampicin, efavirenz). May significantly increase AUC and peak plasma concentration of digoxin. Increased AUC for norethindrone and ethinyl estradiol. Potentially Fatal: Increased risk of myopathy or rhabdomyolysis w/ ciclosporin, gemfibrozil, telaprevir, tipranavir.